Abbott India Limited
Quality (91/100) does the heavy lifting; valuation (22/100) is the drag.
Fair valueOvervaluedAbbott India Limited earns a Hold from StocksWizard, with a blended score of 45/100. We put fair value near ₹18,898.27; at ₹27,800 that leaves roughly 32% downside, so the stock screens overvalued by 32%. On 35.0x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. The price is about 17% below its 52-week high of ₹33,618.32 and 13% above the low of ₹24,604.26. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9. The average analyst target of ₹32,563.38 implies about 17% upside across 8 analysts. It clears 9 of 13 investability checks, with durability 91, valuation 43 and momentum 74 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹15,118.62.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-17.31% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 2/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 34.5%
- Pass: Low debt (D/E < 0.5): 0.04x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 7%
- Pass: Earnings growing: 8%
- Pass: Net margin ≥ 10%: 22.4%
- Pass: Current ratio > 1.5: 2.55
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 21.07
- Fail: Piotroski ≥ 7: 2/9
Quarterly results
Annual financials
Shareholding
- Promoter75.5%
- Institutions7.9%
- Public & other16.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (34.5%).
- Lightly leveraged balance sheet.
- Healthy profit margin (22.4%).
- Financially solid — Altman Z 21.07.
Bear case
Weaknesses
- Weak Piotroski score (2/9).
Threats
- Trades ~32% above our estimated fair value.
About Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics,
Abbott India Limited — frequently asked questions
Is Abbott India Limited a buy, hold or sell?
StocksWizard currently rates Abbott India Limited (ABBOTINDIA) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Abbott India Limited's fair value?
Our blended DCF and relative-valuation model estimates Abbott India Limited's fair value at about ₹18,898.27, versus a current price of ₹27,800 — roughly 32% downside. On that basis the stock looks overvalued by 32%.
Is Abbott India Limited financially healthy?
Abbott India Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9.
How has Abbott India Limited's share price performed?
Abbott India Limited is up 12% over three months, and last traded at ₹27,800. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.